223 related articles for article (PubMed ID: 26765450)
1. Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy.
Hu Z; Liang W; Yang Y; Keefe D; Ma Y; Zhao Y; Xue C; Huang Y; Zhao H; Chen L; Chan A; Zhang L
Medicine (Baltimore); 2016 Jan; 95(2):e2476. PubMed ID: 26765450
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
[TBL] [Abstract][Full Text] [Related]
3. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
4. Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China.
Sun Y; Zheng Y; Yang X; Xie K; Du C; He L; Gui Y; Fu J; Li C; Zhang H; Zhu L; Bie J; Sun Y; Fu Y; Zhou Y; Shou F; Wang Y; Zhu J
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2701-2708. PubMed ID: 33586045
[TBL] [Abstract][Full Text] [Related]
5. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.
Liau CT; Chu NM; Liu HE; Deuson R; Lien J; Chen JS
Support Care Cancer; 2005 May; 13(5):277-86. PubMed ID: 15770489
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy.
Chan A; Low XH; Yap KY
J Manag Care Pharm; 2012 Jun; 18(5):385-94. PubMed ID: 22663171
[TBL] [Abstract][Full Text] [Related]
7. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries.
Hsieh RK; Chan A; Kim HK; Yu S; Kim JG; Lee MA; Dalén J; Jung H; Liu YP; Burke TA; Keefe DM
Support Care Cancer; 2015 Jan; 23(1):263-72. PubMed ID: 25120009
[TBL] [Abstract][Full Text] [Related]
8. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial.
Raftopoulos H; Cooper W; O'Boyle E; Gabrail N; Boccia R; Gralla RJ
Support Care Cancer; 2015 Mar; 23(3):723-32. PubMed ID: 25179689
[TBL] [Abstract][Full Text] [Related]
9. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
Chasen M; Urban L; Schnadig I; Rapoport B; Powers D; Arora S; Navari R; Schwartzberg L; Gridelli C
Support Care Cancer; 2017 Jan; 25(1):85-92. PubMed ID: 27557833
[TBL] [Abstract][Full Text] [Related]
10. Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines.
Yu S; Burke TA; Chan A; Kim HK; Hsieh RK; Hu X; Liang JT; Baños A; Spiteri C; Keefe DM
Support Care Cancer; 2015 Jan; 23(1):273-82. PubMed ID: 25115892
[TBL] [Abstract][Full Text] [Related]
11. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2017 Apr; 22(2):405-412. PubMed ID: 27909835
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.
Tsuji Y; Baba H; Takeda K; Kobayashi M; Oki E; Gotoh M; Yoshida K; Shimokawa M; Kakeji Y; Aiba K
Expert Opin Pharmacother; 2017 Jun; 18(8):753-758. PubMed ID: 28395603
[TBL] [Abstract][Full Text] [Related]
13. Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin.
Zhao Y; Zhao B; Chen G; Chen Y; Liao Z; Zhang H; Feng W; Li Y; Weng H; Li W; Zhou Y; Ren B; Lu Y; Chen J; Liu Z; Su Z; Wang W; Zhang L
Cancer Commun (Lond); 2023 Feb; 43(2):246-256. PubMed ID: 36545810
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice.
Badarudin NS; Mohamed Shah N; Mohd Kassim KNB; Ismail F; Islahudin F; Mohd Tahir NA; Yusak S
Support Care Cancer; 2022 Jun; 30(6):5339-5349. PubMed ID: 35290510
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study.
Keefe DM; Chan A; Kim HK; Hsieh RK; Yu S; Wang Y; Nicholls RJ; Burke TA
Support Care Cancer; 2015 Jan; 23(1):253-61. PubMed ID: 25115893
[TBL] [Abstract][Full Text] [Related]
16. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.
Gilmore JW; Peacock NW; Gu A; Szabo S; Rammage M; Sharpe J; Haislip ST; Perry T; Boozan TL; Meador K; Cao X; Burke TA
J Oncol Pract; 2014 Jan; 10(1):68-74. PubMed ID: 24065402
[TBL] [Abstract][Full Text] [Related]
17. Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice.
Kim HK; Hsieh R; Chan A; Yu S; Han B; Gao Y; Baños A; Ying X; Burke TA; Keefe DM
Support Care Cancer; 2015 Jan; 23(1):293-300. PubMed ID: 25142702
[TBL] [Abstract][Full Text] [Related]
18. Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation.
Stinson J; Chan K; Lee J; Chow R; Cheon P; Giotis A; Pasetka M; Wan BA; Chow E; DeAngelis C
Ann Palliat Med; 2017 Aug; 6(Suppl 1):S13-S20. PubMed ID: 28595433
[TBL] [Abstract][Full Text] [Related]
19. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
